Search
Now showing items 61-70 of 77
Analysis of novel therapeutic options for adenoid cystic carcinoma of the salivary glands
(Institute of Cancer Research (University Of London), 2021-04-30)
Adenoid cystic adenocarcinoma (ACC) of the salivary glands is characterised by slow growth, frequent metastasis and low survival rates. ACC is resistant to conventional chemotherapy and currently, no systemic agent has ...
Optimising trial methodologies to maximise trial efficiencies: a case study in breast cancer radiotherapy trials
(Institute of Cancer Research (University Of London), 2020-01-31)
Background: In an era of falling local relapse rates, the risk-benefit ratio of adjuvant breast radiotherapy requires careful consideration, and the collection of normal tissue effect (NTE) data optimised. For patients at ...
Deciphering the genomic landscape and evolution in multiple myeloma
(Institute of Cancer Research (University Of London), 2020-09-30)
Multiple myeloma (MM) is the second commonest haematological cancer in Western countries, with most patients dying from progressive disease after relapse. Currently, the molecular mechanisms responsible for the initiation ...
Immune and muli-omic profiling for molecular classification and biomarker discovery in soft tissue sarcoma
(Institute of Cancer Research (University Of London), 2020-02-29)
Soft tissue sarcomas (STS) are a group of over 50 rare cancers of mesenchymal origin. Classification of STS is primarily based on histological characteristics of tumours. Novel biomarkers are required that account for the ...
Circulating microRNA-652-3p as a biomarker of regorafenib resistance in metastatic colorectal cancer patients
(Institute of Cancer Research (University Of London), 2020-09-30)
MicroRNAs (miRNAs) are small non-coding RNAs involved in cell homeostasis. MiRNAs dysregulation has been linked with activation of oncogenic pathways, cancer progression and clinical outcome in metastatic colorectal cancer ...
Triplet combination of palbociclib, taselisib and fulvestrant and biomarkers for CDK4/6 and PI3-kinase inhibition in breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Targeting the commonly upregulated cell-cycle and PI3-kinase pathway in breast cancer are two of the most novel approaches to tackle the disease, with both strategies having led to clinically meaningful results and licensed ...
Biological effects of combination therapy with oncolytic reovirus and palbociclib
(Institute of Cancer Research (University Of London), 2021-09-30)
Reovirus type 3 Dearing (RtD3) is an oncolytic dsRNA virus with limited single-agent activity in clinical studies but has potential for use in combination regimens. Herein, I sought to discover synergistic drug-virotherapy ...
Reference dosimetry of MRI-guided radiotherapy machines
(Institute of Cancer Research (University Of London), 2021-09-30)
A cutting-edge cancer treatment modality, that integrates MRI guidance and delivery of radiotherapy (MRIgRT), sets a new standard for personalised radiotherapy. There are, however, aspects around the accurate determination ...
BRCA1 loss-of-function triggers metabolic vulnerability to glutamine deprivation
(Institute of Cancer Research (University Of London), 2021-01-31)
Germline and somatic mutations of BRCA1 are associated with cancer initiation and progression. Although the role of BRCA1 is clearly defined in DNA-repair pathways, alternative functions of BRCA1 still remain obscure. Here, ...
Advanced magnetic resonance imaging in lung mesothelioma
(Institute of Cancer Research (University Of London), 2021-07-31)
Malignant pleural mesothelioma (MPM) has a rind-like growth pattern and may have both solid disease and pleural fluid, so it is very challenging to accurately categorize change in tumour burden using size-based tumour ...